Ascension Cuts Operating Losses to $119.8 Million as Outpatient Strategy Takes Hold

Ascension closed its fiscal 2026 year with $1.5 billion in net income and an operating loss of just $119.8 million, down sharply from the $490.9 billion loss it posted a year earlier. The operating margin improved to -0.2% from -1.6%. For a nonprofit system that has spent three years reshaping its footprint, this is the clearest evidence yet that the strategy is working.

The numbers get better on closer inspection. Strip out one-time transaction costs tied to the $3.9 billion AmSurg acquisition and the bond interest payments issued to fund it, and Ascension's core operations flip into positive territory. On a same-facility basis, income from operations climbed $696 million year over year. Net income rose $826 million.

Total operating revenue reached $24.5 billion for the year ended June 30, against $24.7 billion in operating expenses. Same-facility figures rose 9.8% and 6.5%, respectively. That gap between revenue and expense growth is the story here: Ascension is growing volume and pricing power faster than its cost base, at least for now.

CEO Eduardo Conrado framed the results as validation of a deliberate, multi-year bet. "Three years ago, we set out to strengthen Ascension so we could better serve our patients and communities," he said in the release. "Our results this year show the significant progress we have made."

What's Driving the Turnaround

The core thesis is straightforward: shrink the acute care footprint, expand outpatient capacity, and shift volume toward lower-cost settings. Ascension's same-facility acute case mix index rose 1.7%, a sign the system is treating a higher-acuity, better-reimbursed patient population even as total discharges increased just 1.5%.

Volume growth was broad but modest. Inpatient surgery visits rose 1%, outpatient surgery visits climbed 1.5%, and emergency room visits ticked up 0.8%. None of these figures scream growth story on their own. Together with the case mix shift and a 1% decrease in same-facility average length of stay, they point to a system extracting more value per patient encounter rather than simply seeing more patients.

The AmSurg deal is central to this pivot. Ascension closed the $3.9 billion acquisition this summer after clearing FTC review, which required some ambulatory surgery center divestitures. The purchase pushed Ascension's ASC count to 312, a substantial expansion of its outpatient footprint and a direct hedge against the industry's broader shift away from costly inpatient stays.

Cost discipline has not been the primary lever, and leadership was candid about that. Expenses rose "across all major categories" with the exception of purchased services. Same-facility salaries, wages and benefits increased 3.4%, driven largely by higher volumes, acuity, and a 4.3% jump in average hourly wage. Supply costs rose 9.6% on a same-facility basis, a figure that outpaces revenue growth and warrants attention if it persists.

Nonoperating items did heavy lifting for the bottom line. Nearly $2.1 billion in net investment returns helped convert an operating loss into a $1.5 billion net income figure. That's a familiar pattern among large nonprofit systems with substantial investment portfolios, but it also means the headline net income number reflects market performance as much as operational execution. Investors and rating agencies tracking Ascension's bonds will want to separate the two.

Community benefit spending totaled roughly $2.6 billion on a same-facility basis, with $1.5 billion of that reflecting uncompensated care for Medicare patients. Ascension also flagged service line expansions across Florida, Texas, Wisconsin, Kansas and Tennessee, along with homecare and community-based initiatives, signaling continued capital deployment even as the system works to stabilize margins.

Scale remains a defining feature of Ascension's position. The system operates 91 wholly owned or consolidated hospitals, with noncontrolling interests in 27 more, and employs over 98,000 people. It ranks among the largest nonprofit health systems in the country, which gives it negotiating leverage with payers and suppliers that smaller regional systems lack.

The Bottom Line

Ascension's fiscal 2026 results represent real progress, not a full recovery. The operating margin is still negative. Expense growth in wages and supplies continues to outpace what management would likely prefer, and the swing to net income relied heavily on investment gains rather than operations alone.

That said, the trajectory matters more than any single year's number for a system of this size. A 76% reduction in operating losses, positive core operations once transaction costs are excluded, and $696 million in same-facility operating income improvement are not incremental changes. They reflect a strategy, executed over three years, that appears to be reaching an inflection point.

The AmSurg integration and continued outpatient expansion will be the variables to watch. If Ascension can sustain volume growth in ambulatory settings while holding the line on wage and supply inflation, the path to a positive operating margin looks achievable within the next reporting cycle or two. If cost pressures accelerate faster than outpatient revenue capture, the improvement seen this year could prove harder to repeat. For a nonprofit system managing both mission and margin, that balance will define whether fiscal 2026 marks a turning point or a high-water mark.